Leerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio (NASDAQ:BOLD) with an Outperform rating and a price target of $25.
April 22, 2024 | 7:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners initiated coverage on Boundless Bio with an Outperform rating and a price target of $25.
Analyst ratings, especially those with an Outperform status and a significant price target, can lead to increased investor interest and potentially drive the stock price up in the short term. Given the specificity of the rating and target by a reputable analyst, it's likely to have a positive impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100